{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Patients who are free of disease progression at 4 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","groups":[{"description":"Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.","id":"OG000","title":"Alisertib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 patient did not complete one cycle of treatment and 25 patients were evaluable for efficacy.","reportingStatus":"POSTED","timeFrame":"4 months from treatment started","title":"Disease Control Rate at 4 Months","type":"PRIMARY","unitOfMeasure":"Participants"}